Hi Elizabeth et al.,
I just found the following document.
http://www.aan.com/professionals/practice/pdfs/dementia_guideline.pdf
which summarizes several guidelines with respect to detection, diagnosis,
treatment, and management of dementia (e.g., alzheimer). A colleague of mine
referred me to the following website (American Academy of Neurology):
http://www.aan.com
which has a full version of these guidelines. I wonder if this would be of help
to classify AD patients for inclusion/exclusion in a clinical trial or to
analyze patient data retropectively. I also wonder if this would be of interest
to folks with clinical ontology background.
Thanks,
-Kei
Elizabeth Wu wrote:
Hi Kei,
There is an entry in the Drugs in Clinical Trials section of Alzforum on
Huperzine A http://www.alzforum.org/drg/drc/detail.asp?id=53. The drug is
currently in Phase IV clinical trial in China and phase II in the US. Its
proposed actions are linked to many of the AD hypotheses, and I would think
that if there are sources on research on herbs that could provide more
insight, it would be of interest to the community.
Best,
Elizabeth
Elizabeth Wu
Alzheimer Research Forum
-----Original Message-----
From: [EMAIL PROTECTED]
[mailto:[EMAIL PROTECTED] On Behalf Of
[EMAIL PROTECTED]
Sent: Sunday, May 25, 2008 10:41 PM
To: Tim Clark
Cc: M. Scott Marshall; public-semweb-lifesci@w3.org
Subject: Re: KB note
Hi Tim et al.,
I think it would be great if more details about SWAN can be added. The HCLS
ecosystem consists of scientists, patients, doctors, government agencies,
publishers, etc. Creating/maintaining a balance in this digital age across
national boundaries is challenging/interesting.
Speaking of national boundaries, I wonder if alternative medicine (e.g.,
herbal
medicine) would also be of interest to this community. For example,
Huperzine
is a drug derived from the herb Huperzia serrata. I also wonder if there are
hypotheses regarding the study of herbs in the possible treatment of
neurological diseases.
Thanks,
-Kei
Quoting Tim Clark <[EMAIL PROTECTED]>:
Hi Scott,
Your KB note lists no details about SWAN - we would like to see them
included. I'll forward something to you in a separate email later
today.
Best
Tim
Tim Clark
Director of Informatics, MassGeneral Institute for Neurodegenerative
Disease
Instructor in Neurology, Harvard Medical School
617-947-7098 (mobile)
On May 23, 2008, at 6:59 PM, M. Scott Marshall wrote:
The KB note is ready for a last round of feedback and corrections.
We have until the end of the month to publish so please be speedy
with feedback. You can view the Editor's working draft at:
http://www.w3.org/2001/sw/hcls/notes/kb/
Thanks,
Scott
--
M. Scott Marshall
tel. +31 (0) 20 525 7522
http://staff.science.uva.nl/~marshall
http://adaptivedisclosure.org
